Three successful clinical trials were completed regarding the safety of subretinal injection of 65 kDa retinal pigment epithelium-specific protein (RPE65) expressed by an AAV vector for Leber congenital amaurosis [136,137,138,139]. Here, RPE65 is linked to Leber congenital amaurosis.